Medical Program: The Expanding Value of Biomarkers in NSCLC Treatment

The Expanding Value of Biomarkers in NSCLC Treatment

The Expanding Value of Biomarkers in NSCLC Treatment
RestartResume
New tools are emerging for oncologists as the research into biomarkers continues. How should you be utilizing these molecular signatures?
  • Overview

    The treatment landscape for non-small cell lung cancer is continuing to expand, and playing a major role in clinical decision-making are biomarkers. Dr. Ross Camidge reveals the importance of these molecular signatures with Dr. Shira Johnson and how he applies them in practice. 

    Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

     

Facebook Comments

NEW FEATURES:

Register

Join the Global Oncology Academy of learners.
Registration is free and easy.

Register Now